Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhijie Wang
Institutions:
Henan University of Chinese Medicine,
Nantong University,
Chinese Academy of Medical Sciences & Peking Union Medical College,
State Key Laboratory of Molecular Oncology
Observed institutions:
Henan University of Chinese Medicine,
Nantong University,
Chinese Academy of Medical Sciences & Peking Union Medical College,
State Key Laboratory of Molecular Oncology
ORCID:
0009-0009-9127-1044
Observed ORCID:
0009-0009-9127-1044
OpenAlex ID:
A5121894443
Expert consensus on the detection and clinical application of tumor mutational burden
2026
·
Zhenying Guo
, Chunwei Xu
, et al.
·
Cancer Biology and Medicine
·
4
PDF
Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity
2026
·
Zhijie Wang
, HaiQi He
, et al.
·
European Journal of Medicinal Chemistry
·
4
Recent process in the development of TIM-3 antibodies and small-molecule inhibitors for cancer immunotherapy
2025
·
Fei Huang
, Hao Li
, et al.
·
Bioorganic Chemistry
·
3
Novel Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors Modulate Lipid Metabolism for Enhanced Tumor Immunotherapy
2026
·
Zichao Yang
, Ziqing Liu
, et al.
·
Journal of Medicinal Chemistry
·
1
Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo
2026
·
Xuewen Zhang
, Lirong Zhang
, et al.
·
Bioorganic Chemistry
·
1
Design, synthesis, and anti-AML activity of Hyt-based LSD1 degraders
2026
·
Yanle Zhi
, Ying Gu
, et al.
·
Bioorganic Chemistry
PITRM1-AS1 attenuates the ferroptosis of gastric cancer via TAF1-mediated KDM3B transcription
2026
·
Chenglong Shen
, Haichen Liu
, et al.
·
Scientific Reports
PDF
Show more works
View as search
Works count:
7
Citation count:
13
H-index:
3
I10-index:
Year
Topic
Type